Litigation Details for MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)
✉ Email this page to a colleague
MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)
Docket | ⤷ Try a Trial | Date Filed | 2017-11-26 |
Court | District Court, D. New Jersey | Date Terminated | 2021-03-24 |
Cause | 15:1126 Patent Infringement | Assigned To | Freda L. Wolfson |
Jury Demand | None | Referred To | Douglas Arpert |
Patents | 7,943,788; 8,222,219 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA INC.
Details for MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA INC. (D.N.J. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-11-26 | 1 | States Patent No. 7,943,788 (“the ’788 patent”) and U.S. Patent No. 8,222,219 (“the ’219 patent”) (collectively…collectively, “the patents-in-suit”). This action arises under the patent laws of the United States, 35… THE PATENTS-IN-SUIT 18. On May 17, 2011, the ’788 patent, titled “Glucopyranoside… the ’788 patent. 20. JNV is an exclusive sublicensee of the ’788 patent. … the ’219 patent. 23. JNV is an exclusive sublicensee of the ’219 patent. | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |